J Gynecol Oncol.  2022 Sep;33(5):e67. 10.3802/jgo.2022.33.e67.

Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma

Affiliations
  • 1Department of Perinatology and Gynecology, Kagawa University Graduate School of Medicine, Kida, Japan
  • 2Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
  • 3Department of Clinical Research Center, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
  • 4Department of Diagnostic Pathology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan
  • 5Department of Pathology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
  • 6Department of Pathology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
  • 7Department of Diagnostic Pathology, Nikko Memorial Hospital, Muroran, Japan
  • 8Department of Gynecologic Oncology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
  • 9Department of Obstetrics and Gynecology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan
  • 10Department of Obstetrics and Gynecology, National Defense Medical Collage Hospital, Tokorozawa, Japan
  • 11Department of Gynecology, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan
  • 12Department of Clinical Genetic Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan
  • 13Gynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

Abstract


Objective
To clarify the frequency of deficient mismatch repair (dMMR) in Japanese ovarian cancer patients, we examined microsatellite instability (MSI) status and immunohistochemistry (IHC) subtypes, including endometrioid carcinoma (EMC), clear cell carcinoma (CCC), or a mixture of both (Mix).
Methods
We registered 390 patients who were diagnosed with EMC/CCC/Mix between 2006 and 2015 and treated at seven participating facilities. For 339 patients confirmed eligible by the Central Pathological Review Board, MSI, IHC, and MutL homolog 1 methylation analyses were conducted. The tissues of patients with Lynch syndrome (LS)-related cancer histories, such as colorectal and endometrial cancer, were also investigated.
Results
MSI-high (MSI-H) status was observed in 2/217 CCC (0.9%), 10/115 EMC (8.7%), and 1/4 Mix (25%). Additionally, loss of MMR protein expression (LoE-MMR) was observed in 5/219 (2.3%), 16/115 (14.0%), and 1/4 (25%) patients with CCC, EMC, and Mix, respectively. Both MSI-H and LoE-MMR were found significantly more often in EMC (p<0.001). The median (range) ages of patients with MMR expression and LoE-MMR were 54 (30–90) and 46 (22–76) (p=0.002), respectively. In the multivariate analysis, advanced stage and histological type were identified as prognostic factors.
Conclusion
The dMMR rate for EMC/CCC was similar to that reported in Western countries. In Japan, it is assumed that the dMMR frequency is higher because of the increased proportion of CCC.

Keyword

Ovarian Cancer; Microsatellite Instability; Adenocarcinoma, Clear Cell; Endometrioid; Lynch Syndrome
Full Text Links
  • JGO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr